Adamas Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€75.67M - Cost of goods sold
€1.79M - Gross profit
€73.88M - SG&A expenses
€101.69M - R&D expenses
€5.91M - EBITDA
-€32.63M - D&A
€515.66K - EBIT
-€33.71M - Interest expenses
€20.66M - EBT
-€53.80M - Tax expenses
€569.71K - Net income
-€53.80M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€25.75M - Changes in working capital
€32.74M - Operating cash flow
-€40.17M - Capex
-€18.88K - Other investing cash flow
€31.80M - Net investing cash flow
€6.73M - Total cash dividends paid
€0.00 - Issuance of common stock
-€188.76K - Debt repayment
€0.00 - Other financing cash flow
€57.31M - Net financing cash flow
€57.31M - Foreign exchange effects
€0.00 - Net change in cash
€23.87M - Cash at end of period
€67.46M - Free cash flow
-€40.18M
Balance sheet
- Cash and cash equivalents
€67.46M - Cash and short-term investments
€71.30M - Total receivables
€8.62M - Inventory
€7.45M - Other current assets
€5.30M - Total current assets
€92.67M - Property, plant & equipment
€5.89M - Goodwill
€0.00 - Intangible assets
€589.45K - Long-term investments
€24.02M - Other non-current assets
€373.23K - Total non-current assets
€30.87M - Total assets
€123.53M - Accounts payable
€3.61M - Short-term debt
€3.91M - Other current liabilities
€12.94M - Total current liabilities
€20.46M - Long-term debt
€111.18M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€10.43M - Total non-current liabilities
€121.61M - Total liabilities
€142.07M - Common stock
€42.90K - Retained earnings
-€471.66M - Other equity
€11.15K - Total equity
-€18.54M - Total liabilities and shareholders' equity
€123.53M
Company information
- Market capitalization
€0.00 - Employees
138 - Enterprise Value
€58.30M
Company ratios
- Gross margin
-
97.6% Much better than peer group: -80,146.5% - EBITDA margin
-
-43.1% Much better than peer group: -765.6% - EBIT margin
-
-44.6% Much better than peer group: -816.9% - EBT margin
-
-71.1% Much better than peer group: -214.1% - Net margin
-
-71.1% Much better than peer group: -798.1% - ROE
-
290.2% Much worse than peer group: 2,666.4% - ROA
-
-43.6% Much better than peer group: -133.5% - Asset turnover
-
61.3% Better than peer group: 45.4% - FCF margin
-
-53.1% Much better than peer group: -674.7% - FCF yield
0.0% - Efficiency ratio
143.1% - Net sales per employee
-
€548.31K - Net income per employee
-
-€389.88K